Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- PhRMA/EFPIA Rap Japan’s Drug Pricing Reform, Warn of Grave Consequences
December 21, 2017
- Novo Pres. Bech Re-Elected as EFPIA Japan Chief
December 18, 2017
- GHIT Fund’s New 5-Year Strategic Plan Aims to Win Approval of 2 Products
December 12, 2017
- PhRMA/EFPIA to Govt: Make Major Changes to Drug Pricing Proposal, It Will Tarnish Japan’s Reputation
December 11, 2017
- PhRMA Stands Pat on PMP Push, Says Minor Modification to Govt Proposal “Far from Sufficient”
December 8, 2017
- PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed
November 27, 2017
- Hodanren Petitions Health and Finance Ministers to “Abolish the Price Maintenance Premium”
November 22, 2017
- Patrik Jonsson to Remain PhRMA Japan Chief as Pricing Reform Debate Continues
November 20, 2017
- Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep
November 14, 2017
- Discussions on PMP Should Go Beyond Its Scope: JMA’s Imamura
November 10, 2017
- Lower Price for Better Medicine? Limit Any CEA-Based Re-Pricing to Premium Portion, PhRMA Says
November 6, 2017
- EFPIA Japan Chief Urges Govt to Maintain Support for Innovation
November 2, 2017
- Boehringer’s Thorsten Poehl Named EFPIA Japan Vice Chairman
October 31, 2017
- Global Pharma CEOs Prod Japan to Keep Pro-Innovation Policy, Sound Alarm on Proposed PMP Review
October 31, 2017
- PhRMA, EFPIA Upping Lobbying Campaigns amid Drug Pricing Overhaul
October 30, 2017
- JPMA Reprimands Bayer over Side Effect Reporting Violation, Chides “Inappropriate” Promotion
October 20, 2017
- Securities Analysts Rank Shionogi No. 1 among Drug Markers for “Excellence in Disclosure”
October 17, 2017
- JMA President Yokokura Heads WMA
October 17, 2017
- OTC Switching of Emergency Contraceptive Levonorgestrel Will Be Difficult Under Current System: JPA
October 16, 2017
- Taskforce Discussing Info-Sharing Between Drug Makers in Non-Competitive Fields: JPMA R&D Head
October 12, 2017
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…